More on GRI
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $1.91 |
|
|||
| Open | $1.92 | ||||
| 52 Wk High | $47.03 | ||||
| 52 Wk Low | $37.79 | ||||
| Day High | $2.02 | ||||
| Day Low | $1.87 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 85,829 | ||||
- GRI Bio Featured in "Why Now" On-Demand Video Webcast
- GRI Bio Featured in "Why Now" On-Demand Video Webcast
- GRI Bio to present Phase 2a IPF drug data at ERS Congress in September
- GRI Bio to Present Late-Breaking Phase 2a GRI-0621 Data Highlighting Lung Function, Anti-Fibrotic Biomarkers and Favorable Tolerability in IPF at ERS 2026
- Form 10-Q GRI Bio, Inc. For: Jun 30
- Form SCHEDULE 13G/A GRI Bio, Inc. Filed by: INTRACOASTAL CAPITAL, LLC
- Form 8-K GRI Bio, Inc. For: Jun 18
- FDA grants orphan drug status to GRI Bio's GRI-0621 for lung disease
- GRI Bio Secures FDA Orphan Drug Designation for GRI-0621 (Tazarotene) in Idiopathic Pulmonary Fibrosis
- GRI Bio to Present at A.G.P.’s Annual Healthcare Company Showcase
Entities mentioned with GRI
- Definitive Agreement | View Related Stories »
- Dividend | View Related Stories »
- S1 | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- FDA | View Related Stories »
- Earnings | View Related Stories »
- Show More...
